INCA034176-355 AGAVE-355
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy
Detalhes
Destaques